A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
Exciting progress has been made in the use of gene therapy to treat serious genetic disorders such as sickle cell disease and the thalassemias. Further, allogeneic stem cell transplant is a curative therapy for patients with these disorders. To address the major question of the quality of life after these potentially lifesaving therapies, Badawy and colleagues performed a systematic review of the literature.
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
Recent studies have demonstrated that adolescents and young adults with acute lymphoblastic leukemia (ALL) who are treated with pediatric-inspired regimens have better overall outcomes. However, a concern has been the toxicity of these regimens. Advani and colleagues compared toxicity between CALGB 10403, which is the largest pediatric-inspired study of the treatment of patients with ALL up to age 40, and the Children’s Oncology Study using the same approach.
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Patients treated with CAR T cells often develop cytokine release syndrome, and some patients develop significant coagulopathies. Their management has been an area of significant concern and little practical guidance. Buechner and colleagues address this question and offer guidance.
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
Patients with bronchus-associated lymphoid tissue lymphoma are known to typically have an indolent course. However, the optimal treatment strategy has yet to be defined. Joffe and colleagues evaluated a large number of patients treated with 3 different treatment strategies for event-free and overall survival: active surveillance, systemic chemotherapy or immunotherapy at diagnosis, and complete surgical resection. The results may help define the optimal approach to the treatment of these patients.
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
The treatment of patients with angioimmunoblastic T-cell lymphoma (AITL) remains unsatisfactory. Based upon prior studies combining lenalidomide with CHOP therapy in patients with B-cell lymphoma and the single-agent activity of lenalidomide in the treatment of patients with AITL, Lemonnier and colleagues performed a phase 2 trial of lenalidomide plus CHOP for the treatment of patients with AITL.
Several targeted therapies have been highly effective for the treatment of patients with chronic lymphocytic leukemia, yet resistance can occur. In a Review Article, Skånland and Mato discuss the mechanisms of resistance and strategies to overcome this challenge.